Savara(US:SVRA) Newsfileยท2025-11-06 02:33Core Viewpoint - Rosen Law Firm is encouraging investors of Savara Inc. who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the November 7, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Savara securities between March 7, 2024, and May 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by November 7, 2025 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries in previous years, including over $438 million in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [5]. - It is claimed that the delay in regulatory approval would likely necessitate Savara to raise additional capital, and that the public statements made by the defendants were materially false and misleading [5].